SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol



McCarthy, Caroline, Sacco, Joseph, Fedele, Stefano, Ho, Michael, Porter, Stephen, Liloglou, Triantafillos ORCID: 0000-0003-0460-1404, Greenhalf, Bill, Robinson, Max, Young, Bridget ORCID: 0000-0001-6041-9901, Cicconi, Silvia
et al (show 5 more authors) (2021) SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol. TRIALS, 22 (1). 428-.

This is the latest version of this item.

Access the full-text of this item by clicking on the Open Access link.
[thumbnail of SAVER trial protocol paper.pdf] Text
SAVER trial protocol paper.pdf - Published version

Download (1MB) | Preview

Abstract

<h4>Background</h4>Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, randomised control trial of VPA as a chemopreventive agent in patients with high-risk oral epithelial dysplasia (OED). The aim of the trial is to gather preliminary evidence of the clinical and biological effects of VPA upon OED and assess the feasibility and acceptability of such a trial, with a view to inform a future definitive phase III study.<h4>Methods</h4>One hundred and ten patients with high-risk OED will be recruited from up to 10 secondary care sites in the UK and randomised into either VPA or observation only for 4 months. Women of childbearing potential will be excluded due to the teratogenic properties of VPA. Tissue and blood samples will be collected prior to randomisation and on the last day of the intervention/observation-only period (end of 4 months). Clinical measurement and additional safety bloods will be taken at multiple time points during the trial. The primary outcome will be a composite, surrogate endpoint of change in lesion size, change in grade of dysplasia and change in LOH profile at 8 key microsatellite regions. Feasibility outcomes will include recruitment targets, compliance with the study protocol and adverse effects. A qualitative sub-study will explore patient experience and perception of the trial.<h4>Discussion</h4>The current management options for patients with high-risk OED are limited and mostly include surgical resection and clinical surveillance. However, there remains little evidence whether surgery can effectively lead to a notable reduction in the risk of oral cancer development. Similarly, surveillance is associated with concerns regarding delayed diagnosis of OED progressing to malignancy. The SAVER trial provides an opportunity to investigate the effects of a repurposed, inexpensive and well-tolerated medication as a potential chemopreventive strategy for patients with high-risk OED. The clinical and biological findings of SAVER will inform the appropriateness, design and feasibility of a definitive phase III trial.<h4>Trial registration</h4>The trial is registered with the European Clinical Trials Database ( Eudra-CT 2018-000197-30 ). ( http://www.isrctn.com/ISRCTN12448611 ). The trial was prospectively registered on 24/04/2018.

Item Type: Article
Uncontrolled Keywords: Oral epithelial dysplasia, Sodium valproate, Epigenetic reprogramming, Drug repurposing, Randomised controlled trial, Chemoprevention
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Population Health
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 15 Jul 2021 09:10
Last Modified: 18 Jan 2023 21:35
DOI: 10.1186/s13063-021-05373-8
Open Access URL: https://trialsjournal.biomedcentral.com/articles/1...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3130119

Available Versions of this Item